Physician profile
Steven D Smith
NPI 1376595876
$2,402.56
in general payments reported to CMS, 2019-2025
23 companies · $68.63 in 2025
The $68.63 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $227 · 2021: $194 · 2022: $600 · 2023: $724 · 2024: $34.60 · 2025: $68.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $505.40 | 2019-2023 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $494.51 | 2019-2023 | Trelegy Ellipta, Nucala |
| Amgen INC. | $273.45 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $222.12 | 2019-2025 | Dupixent |
| Pfizer INC. | $133.14 | 2021-2024 | |
| Genzyme Corporation | $110.45 | 2019-2025 | |
| Octapharma USA, INC. | $95.06 | 2019-2022 | |
| Kaleo, INC. | $85.38 | 2019-2023 | Auvi-Q |
| Csl Behring | $72.32 | 2022-2023 | Hizentra |
| Biocryst US Sales Co., LLC | $58.10 | 2022-2023 | Orladeyo |
| Optinose US, INC. | $50.95 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $36.80 | 2019 | |
| Genentech USA, INC. | $34.37 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $30.28 | 2022-2023 | Gammaplex, Coagadex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.63 | 2022 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Alk-Abello, INC | $18.77 | 2019 | |
| Abbvie INC. | $18.01 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.95 | 2019 | |
| Eyevance Pharmaceuticals LLC | $15.00 | 2021 | |
| Shire North American Group INC | $14.26 | 2019 | |
| Merck Sharp & Dohme LLC | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.